Adaptive Biotechnologies Corp vs Invesco Solar ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.94 (market cap $4.04B), while Invesco Solar ETF trades at $52.53. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | TAN | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $25.45 | $73.95 |
52-Week Low | $12.30 | $36.62 |
Enterprise Value | $4.10B | — |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
TAN trades at $53.3, up 2.78% over 24 hours, but technical indicators signal a bearish trend with moving averages showing 11 sell signals versus 2 buys. The ETF faces volatility with a beta of 1.41, as noted by The Motley Fool on August 11, 2026, and recent polysilicon tariffs under the Trump administration have spurred mixed reactions, boosting U.S. solar stocks but raising costs for import-dependent firms, per Reuters on August 7, 2026.
Outlook is cautious due to regulatory uncertainties and high expense ratios, but long-term growth potential exists from AI-driven energy demand. Risks include policy shifts and competition, while institutional sentiment is divided with recent downgrades highlighting valuation concerns.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →